Insider · SEC Form 4 filer
David Mott
Past buys: 2 of 4 beat
Companies
Where they file as an insider
Novavax (NVAX) Director Latest filing Jun 20, 2026
Ardelyx (ARDX) Director Latest filing Jun 16, 2026
Mersana Therapeutics (MRSN) Director Latest filing Jan 6, 2026
Track record
Did their buys beat the typical stock?
Open-market buys9
Quarters checked 6 months later4
Beat the typical stock 2 of 4
Quarters too new to check0
2 of 4 checked quarters beat the typical stock. A past record is data, not a forecast.
Ardelyx (ARDX) Bought Feb 20, 2026 · $1.95M · 333,333 shares Behind typical Mar 31, 2026 $5.99 → Sep 30, 2026 $3.42 · −42.9% (typical stock +1.7%)
Ardelyx (ARDX) Bought May 2–Jun 16, 2025 · $3.4M · 881,377 shares Beat typical Jun 30, 2025 $3.92 → Dec 31, 2025 $5.83 · +48.7% (typical stock +2.1%)
Ardelyx (ARDX) Bought Jan 21–Feb 24, 2025 · $1.38M · 276,729 shares Beat typical Mar 31, 2025 $4.91 → Sep 30, 2025 $5.51 · +12.2% (typical stock +7.3%)
Ardelyx (ARDX) Bought Nov 13–Dec 19, 2024 · $1.99M · 429,168 shares Behind typical Dec 31, 2024 $5.07 → Jun 30, 2025 $3.92 · −22.7% (typical stock −3.4%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.